Clinical Trials Browser

INDUSTRY × Melanoma × tremelimumab × Clear all

NCT03693612 2024-08-28

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Phase 1/2 Completed

26 enrolled 47 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT00378482 2024-08-22

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Phase 2 Completed

37 enrolled 13 charts

DermatologicGastrointestinalGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Phase 1 Completed

BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT00257205 2012-07-02

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Phase 3 Completed

Melanoma

NCT00254579 2012-06-07

Study of CP-675,206 in Refractory Melanoma

Phase 2 Completed

Melanoma

NCT00086489 2012-06-06

CP-675,206 In Patients With Advanced Melanoma

Phase 2 Completed

Melanoma

NCT00431275 2012-06-06

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

Phase 1 Completed

Melanoma

NCT00585000 2012-06-06

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

Phase 1 Terminated

Melanoma